JOHNSON & JOHNSON 853260 - wohl das am konstantesten wachsende Unternehmen der Welt (Seite 36)

[Oberkassel]

Johnson & Johnson: Still A Solid Dividend Growth Pick

http://seekingalpha.com/article/2629665-johnson-and-johnson-…



Hatte Grüne Vorzeichen.

Oberkassler

[Oberkassel]

Is Johnson & Johnson's Worst Nightmare Becoming Reality?

http://www.fool.com/investing/general/2014/10/22/is-johnson-…



Heute grün in NY.

Oberkassler

[sirmike [Blogger]]

In der heutigen Printausgabe von Focus Money findet sich unter dem Ttel "Johnson & Johnson: Gut für die Krise" eine Kaufempfelung; Stopp: 70 EUR.

[sirmike [Blogger]]

Johnson & Johnson: Starttermin für Ebola-Tests

(Quelle) - Der Pharmakonzern Johnson & Johnson (NYSE: JNJ) will ab Januar ein Mittel gegen Ebola an Menschen testen. Sofern die Tests erfolgreich verlaufen, sollen ab Mai eine Viertelmillion Dosen des experimentellen Medikaments zur Verfügung stehen. Es handelt sich um eine Kombination zweier schon zur Verfügung stehender Mittel.

Helmut Gellermann, Frankfurter Tagesdienst, © 2014 Bernecker Börsenbriefe

[Oberkassel]

Vergessen nach der Woche kein wunder !

Johnson & Johnson Declares Quarterly Dividend of $0.70 (JNJ)

21. November ist Ex Dividendentag, Auszahlung ist am 9. Dezember 2014.

http://tickerreport.com/banking-finance/319126/johnson-johns…

Oberkassler

[Oberkassel]

Market Reaction To Johnson & Johnson's Earnings Is Justified

http://www.forbes.com/sites/greatspeculations/2014/10/17/mar…

Recent Purchase: Johnson & Johnson

http://seekingalpha.com/article/2569775-recent-purchase-john…

Heute schöner Anstieg für der Gesamtmarkt

Oberkassler

[Oberkassel]

Johnson & Johnson-Aktie: Positive Kursimpulse erwartet - Hochstufung auf "kaufen", Kurszielerhöhung - Aktienanalyse

http://www.aktiencheck.de/exklusiv/Artikel-Johnson_Johnson_A…



Wird wohl grün heute bleiben - die Zahlen waren insgesamt sehr gut und trotzdem gab es einen Abverkauf gestern. Ich denke heute besinnen sich die Anleger.

Oberkassler

[1435905]

The Biggest Threat Facing Johnson & Johnson
By Todd Campbell

Johnson & Johnson (NYSE: JNJ ) is one of the globe's biggest healthcare companies. Its businesses include everything from Band-Aids to catheters, to cancer busting compounds. But Johnson's status as a dividend paying Goliath doesn't mean it's immune to pitfalls. So we asked some of our top analysts to weigh in with what they believe to be the biggest threats to Johnson going forward. Read below to learn what they think.

Seth Robey: A major story for Johnson & Johnson has been the revival of its pharmaceuticals division. After facing a first wave of patent losses several years ago, a flurry of new drug approvals helped the division grow 11% in 2013 fueling companywide 6% top line growth. That growth appears to be accelerating, with pharmaceutical sales growing a stunning 21% in the most recent quarter. But for all of that success, the division is facing additional patent losses in the coming years that could stall growth.

In 2013, top selling immunology drug Remicade contributed $6.7 billion, or nearly a quarter of the company's pharmaceutical revenue. By 2018, when Remicade loses patent protection in the U.S., those sales could dwindle to mere fractions of what they once were, putting significant strain on the company's fastest growing business. It will be up to newer drugs like Simponi and Stelara to carry Remicade's torch, leaving Johnson & Johnson with the task of convincing doctors that its next generation products have a place in a biosimilar-flooded market.

Todd Campbell: I hear what you're saying Seth, but In my eyes it's the stiffer competition for Johnson's top selling prostate cancer drug, Zytiga, that poses the biggest threat to Johnson & Johnson this year.

Since winning approval in 2011, Zytiga has been a remarkable success, racking up sales of $1.7 billion in 2013 and $1.07 billion through the first six months of 2014.

But sales may slide now that Medivation (NASDAQ: MDVN ) and Astella's (NASDAQOTH: ALPMY ) competing drug, Xtandi, has notched the FDA go-ahead for use in pre-chemotherapy prostate cancer patients.

Despite coming onto the scene more than a year after Zytiga, Xtandi has become the market share leader in the much smaller post-chemotherapy setting and that suggests that its approval for use in the much larger pre-chemotherapy indication will allow it to win substantial market share away from Zytiga there, too. Xtandi's opportunity in the pre-chemotherapy indication is further supported by its label, which includes language noting its ability to improve overall survival -- something that Zytiga can't claim.

Since Zytiga is one of Johnson's top selling drugs this year, a drop-off in sales could weigh down its profit, so investors should pay close attention to Johnson's next few earnings reports to see if Zytiga's momentum stalls.

George Budwell: But it's not just Zytiga that has allowed J&J to be a top performer in the Dow this year, it's the company's hepatitis C drug Olysio, too. In the second quarter, Olysio hit blockbuster status by posting $725 million in sales during the quarter.

The drug's monstrous performance has been somewhat surprising given that it was up against Gilead Sciences' (NASDAQ: GILD ) terminator hep C drug Sovaldi. But as it turns out, doctors have been co-prescribing the two drugs at a fairly nice clip, leading to Olysio's unexpectedly strong sales.

Even so, I think Olysio may have already peaked only about half a year into its U.S. launch. Within the next four to five months, we should see a glut of new hepatitis C drugs, from the likes of AbbVie and Bristol-Myers Squibb, hit the market that will surely cut into Olysio sales. Perhaps more importantly, the likely approval of the fixed-dosed combo pill of ledipasvir and Sovaldi later this year should make Olysio co-prescriptions unnecessary, in most cases. All told, I think most of the drug's $2 billion-plus in projected 2014 sales could be wiped out in 2015.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here.

Todd Campbell owns shares of Gilead Sciences and Medivation. George Budwell owns shares of Johnson & Johnson. Seth Robey doesn't own positions in the companies mentioned. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Gilead Sciences and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

[1435905]

Johnson & Johnson kauft Alios BioPharma für 1,75 Mrd US-Dollar

Der US-Pharmakonzern Johnson & Johnson (J&J) kauft das Biopharmaunternehmen Alios für 1,75 Milliarden US-Dollar in bar. Die nicht börsennotierte Alios BioPharma konzentriert sich auf die Entwicklung von Therapien für Viruserkrankungen. Das Portfolio umfasst unter anderem AL-8176, eine potenzielle Therapie zur Behandlung von Kleinkindern, die sich mit sogenannten Respiratorischen Syncytial-Viren (RSV) infiziert haben.

Solche Virus sind bei Kleinkindern bis zum Alter von drei Jahren weltweit der häufigste Auslöser von akuten Atemwegsinfektionen. Sie verursachen etwa Schnupfen, Husten, akute Bronchitis oder Mittelohrentzündung. Die Infektionen können in den ersten drei Lebensmonaten besonders schwer verlaufen. RSV sei die letzte der großen Kinderkrankheiten, für die es keine präventive Behandlung gebe, erklärte J&J.

Der Deal soll im vierten Quartal abgeschlossen werden.


Quelle: Dow Jones

[Oberkassel]

Johnson & Johnson: High Profitability, Trading Below Fair Value

http://seekingalpha.com/article/2449195-johnson-and-johnson-…

Oberkassler